范式转变中证据的侵蚀:卫生技术评估中叙事合理性的兴起
本文描述药物监管与卫生技术评估中三种部分共存的证据配置,并检验从重复验证向连贯性证明标准转变的推断后果。两试验范式假阳性后验概率约0.3%,单试验范式约4%-9%,叙事范式可能超过15-20%。FDA基于至少两项关键随机试验的批准比例从1995-1997年的80.6%降至2015-2017年的52.8%。
要点
- 证据标准从重复验证向连贯性证明转变,假阳性风险递增。
- 两试验范式假阳性后验概率约0.3%,单试验范式约4%-9%。
- 叙事范式下假阳性后验概率可能超过15-20%。
核心结论
- 维持HTA的关键功能需要灵活的证据框架,以保留独立比较评估、分析透明度和不确定性的明确管理。
- 缺乏此类保障时,基于连贯性的推断可能使证据标准转向合理性和机构可接受性,而非实证检验。
- 这一转变应被理解为证据标准的转变,而不仅仅是研究设计的技术调整。
研究设计与样本
- 概念与方法学评论,基于监管历史、已发表的方法学和流行病学文献、监管审批模式的实证趋势及说明性监管案例。
- 正式定义并比较三种证据配置:两试验范式、单试验范式和叙事范式。
主要发现
- 两试验范式源于Kefauver-Harris法案后对充分且良好对照研究的强调,并在1980年代末和1990年代FDA监管实践中巩固。
- 在现实先验假设下,两试验范式可能产生约0.3%的假阳性后验概率。
- 单试验范式由1997年FDA现代化法案进一步合法化,允许一项充分且良好对照试验辅以确证性证据,在可比假设下估计假阳性后验概率约为4%-9%。
- 叙事范式通过加速审批路径、替代终点依赖、单臂试验设计、外部对照、真实世界证据和外推策略逐步扩展;在该配置下,假阳性后验概率可能进一步增加(可能>15-20%),取决于先验概率、终点有效性和研究设计。
- 已发表趋势显示,FDA基于至少两项关键随机试验的批准比例从1995-1997年的80.6%下降至2015-2017年的52.8%。
临床怎么用
- 监管机构、HTA机构和指南制定组织在部分不同的机构授权下运作,并以不同的证据阈值和决策目的应用这些配置。
- 皮下注射贝利尤单抗在儿童系统性红斑狼疮中的开发路径说明,在特定情况下基于重复的证据可能辅以药代动力学桥接和外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe and characterize three partly coexisting evidentiary configurations in drug regulation and health technology assessment (HTA), and to examine the inferential consequences of the progressive shift from replication-based to coherence-oriented standards of proof. STUDY DESIGN AND SETTING: Conceptual and methodological commentary drawing on regulatory history, published methodological and epidemiological literature, documented empirical trends in regulatory approval patterns, and illustrative regulatory cases. Three evidentiary configurations are formally defined and compared: the two-trial paradigm, the one-trial paradigm, and a narrative regime characterized by coherence-based justification when independent experimental replication is limited or absent. RESULTS: The two-trial paradigm emerged from the post-Kefauver-Harris regulatory emphasis on adequate and well-controlled investigations and was consolidated in U.S. Food and Drug Administration (FDA) regulatory practice in the late 1980s and 1990s. Under realistic prior assumptions, this configuration may yield a posterior probability of false positive finding (PPFP) of approximately 0.3%. The one-trial paradigm was further legitimized by the FDA Modernization Act (1997), which allowed one adequate and well-controlled trial to be supported by confirmatory evidence, with estimated PPFPs of approximately 4%-9% under comparable assumptions. A third configuration, here termed the narrative regime, has expanded progressively through accelerated approval pathways, surrogate endpoint reliance, single-arm trial designs, external controls, real-world evidence, and extrapolation strategies; under this configuration, PPFP may increase further (potentially >15-20%), depending on the prior probability, endpoint validity, and study design. Published trends document a decline in FDA approvals supported by at least two pivotal randomized trials, from 80.6% in 1995-1997 to 52.8% in 2015-2017. The development pathway of subcutaneous belimumab in pediatric systemic lupus erythematosus (SLE) illustrates how replication-based evidence may be supplemented by pharmacokinetic bridging and extrapolation in selected settings. Regulatory agencies, HTA bodies, and guideline-development organizations operate under partly distinct institutional mandates and apply these configurations with different evidentiary thresholds and decision purposes. CONCLUSION: Maintaining the critical function of HTA requires flexible evidentiary frameworks to preserve independent comparative evaluation, analytical transparency, and explicit management of uncertainty. Without such safeguards, coherence-based inference may shift evidentiary standards toward plausibility and institutional acceptability rather than empirical testing. This shift should therefore be understood as a transformation in evidentiary standards, not merely as a technical adaptation of study designs.
引用
- Lega JC, Gougeon A, Michal C, et al. The erosion of proof in paradigm transitions: the rise of narrative rationality in health technology assessment. J Clin Epidemiol. 2026. PMID: 42580367. doi:10.1016/j.jclinepi.2026.112458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。